Cost Of Reviewing Drugs With AI Is ‘Prohibitive’ For US FDA

 
• By Sarah Karlin-Smith
  
Super Computer
The FDA lacks the necessary funding to review applications with AI and machine learning. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from AI

More from Advanced Technologies